Daré Bioscience (NASDAQ:DARE – Get Free Report) posted its earnings results on Monday. The biotechnology company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.02, Zacks reports.
Daré Bioscience Stock Performance
Shares of Daré Bioscience stock traded up $0.01 during trading on Monday, hitting $2.89. The company’s stock had a trading volume of 30,644 shares, compared to its average volume of 45,577. The company has a fifty day simple moving average of $3.07 and a two-hundred day simple moving average of $3.29. Daré Bioscience has a 52 week low of $2.67 and a 52 week high of $7.56. The company has a market capitalization of $25.14 million, a PE ratio of -4.89 and a beta of 1.38.
Analyst Ratings Changes
Separately, HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Daré Bioscience in a report on Tuesday, December 17th.
Daré Bioscience Company Profile
Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.
Featured Articles
- Five stocks we like better than Daré Bioscience
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Buyable Stocks With Solid Bottoms Ready to Rebound
- Why Are These Companies Considered Blue Chips?
- Advantage+ Shopping: Meta’s Fast Growing $20 Billion AI-Ads Star
- How Technical Indicators Can Help You Find Oversold Stocks
- Robotaxi News: What Tesla and Lyft Headlines Mean for Shares
Receive News & Ratings for Daré Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daré Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
